Strategic alliances can provide additional resources that expedite the development of novel therapies and make them available more quickly to patients in need of new treatment options. We evaluate collaboration, in-licensing, and out-licensing opportunities that have the potential to complement our existing expertise and pipeline assets, and to advance our current pipeline programs toward commercialization.
We are interested in evaluating collaboration opportunities that help us advance our clinical and pre-clinical pipeline for the benefit of patients and our investors. See our pipeline for more details.
Oncothyreon is currently seeking partnering opportunities for our proprietary adjuvant PET-Lipid A.
Synthetic Lipid-A Analogs
Cascadian Therapeutics' PET-Lipid A, a fully-synthetic toll-like receptor 4 (TLR4) agonist, has been manufactured under cGMP as an adjuvant for vaccine formulations for clinical trials. In preclinical studies PET-Lipid A was found to be approximately 10-times more potent than MPL®, a TLR agonist used in an FDA-approved, commercially available vaccine. PET-Lipid A is a component of ONT-10, our second generation therapeutic vaccine currently in Phase 1 development.
Click here for additional information on PET-Lipid A.
We seek to expand our pipeline of oncology product candidates, both small molecules and immunotherapy, leveraging our strong translational scientific and clinical development expertise. We prioritize opportunities that are at a "development candidate stage" (e.g., ready for GLP toxicology) or later, including clinical stage opportunities. We are flexible in our approach. Share your opportunity with us email@example.com.
For more information on business development opportunities at Cascadian Therapeutics, contact Guy Cipriani.